M42 And Uzbekistan's Ministry Of Health Sign MoU To Advance Uzbek Genome Programme And Healthcare Initiatives

M42 has partnered with Uzbekistan's Ministry of Health to explore strategic collaborations on the Uzbek Genome Programme. This agreement, formalised through a Memorandum of Understanding (MoU), was signed at Rotana Beach, Abu Dhabi. Key figures present included Farhkodjon Tashpulatov, Uzbekistan’s Deputy Minister of Health, and Dr. Fahed Al Marzooqi from M42.

The collaboration aims to enhance genomics capabilities in Uzbekistan. It focuses on developing genomic tools for better understanding genetic diversity and diseases within the country. The initiative also seeks to create scalable screening and diagnostic tools for early disease detection and prevention.

One of the primary objectives is to support genetically inherited disease prevention programmes. This includes pre-marital, newborn, and non-invasive prenatal testing. The partnership will also expand efforts to address diseases like cancer and cardiovascular conditions.

Additionally, the agreement supports research and development in novel screening methods. These initiatives aim to manufacture and export diagnostics "made in Uzbekistan." Knowledge transfer and workforce upskilling are also key components of this collaboration.

M42's experience with the Emirati Genome Programme has been instrumental in building a local genetic database. This expertise will be leveraged to benefit Uzbekistan by advancing early disease detection and shifting healthcare towards prevention.

The build, operate, and transfer model will be explored to implement these genomics advancements effectively. This approach aims to tackle disease risks specific to the Uzbek population.

Comments from Key Stakeholders

Farhkodjon Tashpulatov stated that genomic research provides unique opportunities for understanding Uzbek genetic traits. "We are proud to be part of a global initiative in genomic research aimed at improving population health," he remarked.

Hasan Jasem Al Nowais highlighted the transformative nature of this partnership for Uzbekistan's healthcare system. He noted that underrepresented populations often miss out on benefits like advanced clinical care due to lack of diversity in genomic research.

Future Prospects

The Uzbek Genome Programme is expected to address gaps in global healthcare by tackling genetic disease causes. It aims to improve patient outcomes while reducing chronic disease burdens for Uzbekistan's people.

Dr Fahed Al Marzooqi emphasised M42's role in shifting healthcare from reactionary measures to preventive strategies. "We have built a powerful genomics engine delivering end-to-end capabilities," he said.

This partnership marks a significant step towards creating sustainable health solutions for Uzbekistan and contributing globally to health equity improvements.

With inputs from WAM